期刊文献+

HCV NS3对IFN-λⅠ表达的影响及其调控机制

Effects and regulation mechanisms of HCV NS3 on expression of IFN\|λⅠ in HepG2 cells
原文传递
导出
摘要 目的探讨丙型肝炎病毒(HCV)NS3对干扰素-λⅠ(IFN-λⅠ/IL-29)表达的影响及其调控机制。方法将HCV NS3表达载体pcDNA3.1/myc-His-NS3转染至HepG2细胞,验证HCV NS3蛋白表达之后,采用实时荧光定量PCR、Westernblot和ELISA法观察HCV NS3对IFN-λⅠmRNA及其蛋白表达水平的影响。构建IFN-λⅠ全长启动子报告基因表达载体和3’-非翻译区(3’-UTR)报告基因表达载体,借助双萤光素酶活性检测,探索HCV NS3对IFN-λⅠ转录水平的调控机制。结果 pcDNA3.1/myc-His-NS3在HepG2细胞中成功表达,与转染pcDNA3.1/myc-His空载体相比,pcDNA 3.1/myc-His-NS3过表达时在mRNA和蛋白水平均能抑制HepG2细胞内IFN-λⅠ的表达,差异具有统计学意义(P<0.05)。双萤光素酶活性检测结果显示,与对照组相比,转染IFN-λⅠ全长启动子和3’-非翻译区报告基因表达质粒后,双萤光素酶活性变化无统计学意义(P>0.05)。结论 HCV NS3在mRNA及蛋白水平能抑制IFN-λⅠ的表达,但其转录水平不受影响,具体调控机制尚有待进一步研究。 Objective To investigate on the effects and regulation mechanisms of HCV NS3 on IFN-λI (IL-29) in HepG2 cells. Methods HCV NS3 protein expressive vector was cloned (pcDNA3. l/ myc-His-NS3) and expressed in HepG2 cells, then the expression level of IFN-λI was detected by qRT-PCR, Western blot and ELISA. IFN-λI promoter reporter vector (pGIA. 10-IFN-λI P) as well as the IFN-λI 3' -untranslated region (3'-UTR) reporter vector (pmirGLO-IFN-λ I 3'-UTR) were constructed and used for studying the regulation mechinasm by luciferase assay. Results HCV NS3 protein expressed in HepG2 cells post-transfection successfully. Both the mRNA and protein expression levels were significantly decreased in the presence of HCV NS3 protein (P 〈 0.05). However, the results of iuciferase assay showed that HCV NS3 protein had no influence on IFN-λ I promoter activity. In addition, miRNAs were involved in the regulation of IFN-λI by HCV NS3 protein. Conclusions Overexpression of HCV NS3 could inhibit the expression of IFN-λI , but the specific regulatory mechanism is still not clear.
出处 《中华实验和临床感染病杂志(电子版)》 CAS 2013年第1期1-4,共4页 Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition)
基金 国家"十二五"传染病重大专项(No.2012ZX10002003) 北京市科委重大项目(No.D09050703560908) 北京市卫生系统高层次卫生技术人才"领军人才"项目(No.2009-1-09)
关键词 肝炎病毒 丙型 NS3基因 干扰素-λⅠ 调控 Hepatitis C virus NS3 gene Interferon-λI Regulation
  • 相关文献

参考文献12

  • 1Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology, 2009,49(4) : 1335-1374.
  • 2Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology ,2010,53 ( 3 ) : 1020-1022.
  • 3Manns MP, MeHutchison JG, Gordon S, et al. Peginterfem alpha- 2b plus ribavirin compared to interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C. A randomized trail. Lancet, 2001,358(9286) :958-965.
  • 4Fied MW, Schiffman MI, Reddy R, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Eng J Med, 2002,347 ( 13 ) :975-982.
  • 5Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev ,2007,20( 1 ) :23-38.
  • 6Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature,2009,461 (7262) :399-401.
  • 7Kotenko SV, Gallagher G, Baurin VV, et al. lFN-lambdas mediate antiviral protection through a distinct class 1I cytokine reeeptor complex. Nat Immunol,2003,4( 1 ) :69-77.
  • 8Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol, 2003,4 ( 1 ) : 63-68.
  • 9Renauid JC. Class 1I cytokine receptors and their |igands: key antiviral and inflammatory modulators. Nature Rev Immunol,2003,3 (8) :666-676.
  • 10成军.慢性丙型肝炎直接抗病毒药物耐药研究进展[J].首都医科大学学报,2012,33(4):530-533. 被引量:3

二级参考文献46

  • 1Pagliacetti NE,Robek MD.Interferon-λ in the immune response to hepatitis B virus and hepatitis C virus[J].J Interferon Cytokine Res,2010,30(8):585-590.
  • 2Sheppard P,Kindsvogel W,Xu W,et al.IL-28,IL-29 and their class Ⅱ cytokine receptor IL-28R[J].Nature Immunol,2003,4(1):63-68.
  • 3Kotenko SV,Gallagher G,Baurin VV,et al.IFN-λs mediate antiviral protection though a distinct class Ⅱcytokine reptor complex[J].Natuare Immunol,2003,4(1):69-77.
  • 4Renauld JC.Class Ⅱ cytokine receptors and their ligands:key antiviral and inflammatory modulators[J].Nature Rev Immunol,2003,3(8):666-676.
  • 5Langhans B,Kupfer B,Braunschweiger I,et al.Interferon-lamda serum levels in hepatitis C[J].J Hepatol,2011,54(5):859-865.
  • 6Sommereyns C,Paul S,Staeheli P,et al.IFN-lambda(IFN-lambda)is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo[J].PLoS Pathog,2008,4(3):e1000017.
  • 7Lasfar A,Lewis-Antes A,Smirnov SV,et al.Characterization of the mouse IFN-λ ligand-receptor sysrem:IFN-λs exhibit antitumor activity against B16 melanoma[J].Cancer Res,2006,66(8):4468-4477.
  • 8Foy E,Li K,Sumpter R,et al.Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-Ⅰ signal[J].Froc Natl Sci U S A,2005,102(8):2986-2991.
  • 9Foy E,Li K,Wang C,et al.Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease[J].Science,2003,300(5622):1145-1148.
  • 10Li K,Foy E,Ferreon JC,et al.Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Too-like receptor 3 adaptor protein TRIF[J].Proc Natl Acad Sci U S A,2005,102(8):2992-2997.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部